Alain Matagne - Concepedia

Author

Alain Matagne

UCB Pharma (Belgium)

Also Known As

A MATAGNE, A Matagne, A. Matagne, ALAIN MATAGNE, Alain C. Matagne, Alain Matagne, Matagne, A

Publications

4.5K

Citations

H-Index

Concepts

All Affiliations

UCB Pharma (Belgium)University of California, Los Angeles UCB Pharma (Germany)University of Liège

About

Alain Matagne is an author at UCB Pharma (Belgium) specializing in medicine, neuroscience, and social sciences.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	12	12	2.6K
2	Social Sciences	11	11	2.3K
3	Engineering	1	1	31
4	Natural Sciences	1	1	222
5	Biochemistry	1	1	222

Alain Matagne

Publications

3.9K

Citations

H-Index

Page 1

	Year	Citations
The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam Berkley A. Lynch, Nathalie Lambeng, Karl Nocka, Proceedings of the National Academy of Sciences New Antiepileptic DrugMolecular NeuroscienceAntiepileptic Drug LevetiracetamNeurophysiologyMedicine	2004	1.6K
The anti‐epileptic drug levetiracetam reverses the inhibition by negative allosteric modulators of neuronal GABA‐ and glycine‐gated currents Jean‐Michel Rigo, Grégory Hans, Laurent Nguyen, British Journal of Pharmacology	2002	332
The novel antiepileptic drug levetiracetam (ucb L059) appears to act via a specific binding site in CNS membranes Michel Noyer, Michel Gillard, Alain Matagne, European Journal of Pharmacology MedicineCns MembranesNeuropharmacologyNeurologyNeurotransmission	1995	253
Discovery of 4-Substituted Pyrrolidone Butanamides as New Agents with Significant Antiepileptic Activity Benoît Kenda, Alain Matagne, Patrice Talaga, Journal of Medicinal Chemistry New AgentsDrug TargetPharmaceutical ScienceLbs AffinityPharmacotherapy	2003	222
Anti‐convulsive and anti‐epileptic properties of brivaracetam (ucb 34714), a high‐affinity ligand for the synaptic vesicle protein, SV2A Alain Matagne, D‐G Margineanu, Benoît Kenda, British Journal of Pharmacology	2008	219
SV2A protein is a broad-spectrum anticonvulsant target: Functional correlation between protein binding and seizure protection in models of both partial and generalized epilepsy Rafał M. Kamiński, Alain Matagne, Karine Leclercq, Neuropharmacology Generalized EpilepsyNeurophysiologySeizure ProtectionNeurologyNeuroscience	2007	166
Brivaracetam, a selective high‐affinity synaptic vesicle protein 2A (<scp>SV</scp>2A) ligand with preclinical evidence of high brain permeability and fast onset of action Jean‐Marie Nicolas, Jonas Hannestad, Daniel Holden, Epilepsia	2015	159
Validation of corneally kindled mice: a sensitive screening model for partial epilepsy in man Alain Matagne, Henrik Klitgaard Epilepsy Research OphthalmologyNeurophysiologyNeuroanatomyPartial EpilepsyExperimental Ophthalmology	1998	126
Proepileptic phenotype of SV2A‐deficient mice is associated with reduced anticonvulsant efficacy of levetiracetam Rafał M. Kamiński, Michel Gillard, Karine Leclercq, Epilepsia	2009	115
Anticonvulsant effects of levetiracetam and levetiracetam–diazepam combinations in experimental status epilepticus Andréy Mazarati, Roger A. Baldwin, Henrik Klitgaard, Epilepsy Research Experimental Status EpilepticusNeurophysiologyMedicinePsychotropic MedicationNeuromodulation Therapies	2004	112

Page 1